Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded diagnostics company.
Alacrita identified pharma companies active in the therapeutic area of interest and screened their attractiveness as potential partners (e.g. companion diagnostics). We identified sources of strategic equity investment from both pharma and the diagnostics industry. We assessed the feasibility of developing a future test kit from the existing LDT and identified global partners with the most appropriate technological and commercial capabilities. Alacrita developed a list of partners for the company's current assay in Europe, Japan, China and Korea, screening each partner for strategic, infrastructure, technology and sales/marketing fit. For each potential partner, we identified key contacts within each company, providing the client with an actionable business development roadmap.
Alacrita was subsequently asked to conduct an in depth, systematic search for new diagnostics intellectual property in the therapeutic area of interest and other, closely aligned therapy areas. We conducted a thorough search of patent and literature databases stratifying potential biomarker and diagnostics opportunities by DNA, RNA and epigenetics. Alacrita unearthed a number of diagnostics in-licensing opportunities which the client then pursued, helping buttress the company’s leadership in the field.Back